CPC A61K 39/12 (2013.01) [A61K 39/125 (2013.01); A61K 39/39 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55572 (2013.01); A61K 2039/70 (2013.01); C12N 2770/16034 (2013.01)] | 21 Claims |
1. A method of eliciting protective immunity against Norovirus in a human comprising administering parenterally to the human no more than a single dose of a vaccine composition, said composition comprising
(i) genogroup I Norovirus virus-like particles (VLPs), wherein said genogroup I Norovirus VLPs comprise a capsid protein derived from a genogroup I viral strain, or
(ii) genogroup II Norovirus VLPs, wherein said genogroup II Norovirus VLPs comprise a capsid protein derived from a genogroup II viral strain,
wherein said composition induces at least a three-fold increase in Norovirus-specific serum antibody titer as compared to the titer in the human prior to administration of the composition, and
wherein the composition comprises about 5 μg to about 150 μg of said genogroup I or genogroup II Norovirus VLPs.
|